METHYLPHENIDATEPlacebo manufactured by the hospital pharmacy of the Capital Region in Denmark; The placebo product does not contain active substance and is otherwise identical to the IMP after preparation.
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
Time to awakening, defined as first sustained improvement in consciousness (FOUR, e = 4; or FOUR, total score ≥12; or SECONDs ≥6; confirmed on two consecutive exams 1h apart).
Endpoint detail
Proportion of patients achieving clinical arousal, ICU mortality and length of stay, 3-month outcome (mRS, CPC, GOS-E)
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.